Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GKOS NYSE:INSP NASDAQ:NARI NYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGKOSGlaukos$106.65+1.8%$96.39$77.10▼$163.71$6.09B0.82918,291 shs441,420 shsINSPInspire Medical Systems$139.27+3.6%$140.04$123.00▼$225.00$4.11B1.25555,184 shs901,968 shsNARIInari Medical$79.97$79.97$39.76▼$79.99$4.68B1.021.45 million shsN/AWRBYWarby Parker$22.23-0.2%$20.32$12.46▼$28.68$2.32B2.091.99 million shs1.82 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGKOSGlaukos+2.42%+1.31%+11.11%+18.06%-13.66%INSPInspire Medical Systems+0.64%+2.97%-1.47%-6.91%+2.25%NARIInari Medical0.00%0.00%0.00%0.00%+56.37%WRBYWarby Parker-0.62%+1.46%-0.86%+46.72%+41.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGKOSGlaukos4.3843 of 5 stars4.41.00.04.42.51.70.6INSPInspire Medical Systems4.8176 of 5 stars4.41.00.04.82.92.51.9NARIInari MedicalN/AN/AN/AN/AN/AN/AN/AN/AWRBYWarby Parker1.9431 of 5 stars2.33.00.00.01.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGKOSGlaukos 2.75Moderate Buy$134.6726.27% UpsideINSPInspire Medical Systems 2.73Moderate Buy$211.9152.16% UpsideNARIInari Medical 2.14Hold$69.22-13.44% DownsideWRBYWarby Parker 2.53Moderate Buy$22.882.92% UpsideCurrent Analyst Ratings BreakdownLatest WRBY, GKOS, NARI, and INSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025WRBYWarby ParkerJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform7/10/2025WRBYWarby ParkerCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/29/2025WRBYWarby ParkerPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$20.00 ➝ $25.005/22/2025WRBYWarby ParkerRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$18.00 ➝ $21.005/21/2025WRBYWarby ParkerCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$17.00 ➝ $22.005/21/2025WRBYWarby ParkerStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$18.00 ➝ $21.005/21/2025WRBYWarby ParkerTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $24.005/13/2025WRBYWarby ParkerUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$23.00 ➝ $20.005/6/2025GKOSGlaukosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGKOSGlaukos$383.48M15.89N/AN/A$13.91 per share7.67INSPInspire Medical Systems$840.11M4.89$1.78 per share78.11$23.01 per share6.05NARIInari Medical$493.63M9.48$0.09 per share906.95$8.07 per share9.91WRBYWarby Parker$771.32M3.01$0.34 per share65.75$3.35 per share6.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGKOSGlaukos-$146.37M-$2.37N/AN/AN/A-31.40%-10.66%-8.06%7/30/2025 (Estimated)INSPInspire Medical Systems$53.51M$2.1764.1843.252.047.92%10.00%8.68%8/5/2025 (Estimated)NARIInari Medical-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/AWRBYWarby Parker-$20.39M-$0.12N/A222.25N/A-1.79%-2.48%-1.29%8/6/2025 (Estimated)Latest WRBY, GKOS, NARI, and INSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025INSPInspire Medical Systems$0.22N/AN/AN/A$214.50 millionN/A7/30/2025Q2 2025GKOSGlaukos-$0.26N/AN/AN/A$115.49 millionN/A5/5/2025Q1 2025INSPInspire Medical Systems-$0.23$0.10+$0.33$0.10$194.89 million$201.32 million4/30/2025Q1 2025GKOSGlaukos-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGKOSGlaukosN/AN/AN/AN/AN/AINSPInspire Medical SystemsN/AN/AN/AN/AN/ANARIInari MedicalN/AN/AN/AN/AN/AWRBYWarby ParkerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGKOSGlaukos0.096.495.62INSPInspire Medical SystemsN/A9.017.44NARIInari MedicalN/A1.771.40WRBYWarby ParkerN/A2.702.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGKOSGlaukos99.04%INSPInspire Medical Systems94.91%NARIInari Medical90.98%WRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipGKOSGlaukos5.80%INSPInspire Medical Systems4.10%NARIInari Medical10.60%WRBYWarby Parker18.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGKOSGlaukos78057.14 million53.83 millionOptionableINSPInspire Medical Systems1,24629.49 million28.29 millionOptionableNARIInari Medical80058.54 million52.34 millionOptionableWRBYWarby Parker3,780104.50 million85.44 millionOptionableWRBY, GKOS, NARI, and INSP HeadlinesRecent News About These CompaniesWarby Parker (NYSE:WRBY) Receives "Market Perform" Rating from JMP SecuritiesJuly 10 at 9:55 AM | marketbeat.comWarby Parker (NYSE:WRBY) Stock Rating Lowered by Citizens JmpJuly 10 at 8:52 AM | marketbeat.comWarby Parker Inc. Stock Grades | WRBY - Barron'sJuly 10 at 4:35 AM | barrons.comWarby Parker Inc. (NYSE:WRBY) Receives $22.88 Average PT from AnalystsJuly 9 at 3:35 AM | americanbankingnews.comWinners And Losers Of Q1: Warby Parker (NYSE:WRBY) Vs The Rest Of The Beauty and Cosmetics Retailer StocksJuly 8 at 11:55 AM | msn.comWarby Parker Inc. (NYSE:WRBY) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 6, 2025 | americanbankingnews.comWarby Parker Inc. (NYSE:WRBY) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 6, 2025 | marketbeat.com11,751 Shares in Warby Parker Inc. (NYSE:WRBY) Acquired by Diversified Trust CoJuly 2, 2025 | marketbeat.comWhat Makes Warby Parker (WRBY) an Attractive Investment?June 30, 2025 | finance.yahoo.comBessemer Group Inc. Has $1.17 Million Stock Position in Warby Parker Inc. (NYSE:WRBY)June 30, 2025 | marketbeat.comWRBY - Warby Parker Inc Ordinary Shares - Class A Chart - MorningstarJune 28, 2025 | morningstar.comMThe 5 Most Interesting Analyst Questions From Warby Parker’s Q1 Earnings CallJune 27, 2025 | msn.comWarby Parker (NYSE:WRBY) Stock Price Down 3.7% - Here's What HappenedJune 26, 2025 | marketbeat.comSG Americas Securities LLC Buys Shares of 33,023 Warby Parker Inc. (NYSE:WRBY)June 22, 2025 | marketbeat.comWarby Parker (WRBY): Buy, Sell, or Hold Post Q1 Earnings?June 20, 2025 | msn.comRiverwater Partners LLC Invests $460,000 in Warby Parker Inc. (NYSE:WRBY)June 20, 2025 | marketbeat.comVaughan Nelson Investment Management L.P. Trims Stake in Warby Parker Inc. (NYSE:WRBY)June 15, 2025 | marketbeat.comTech Giants Partner With Retailers As Smart Glasses Battle Heats UpJune 12, 2025 | forbes.comWarby Parker eyes space at trendy Raleigh shopping centerJune 11, 2025 | bizjournals.comWarby Parker Inc. (NYSE:WRBY) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 11, 2025 | marketbeat.comWRBY Q1 Earnings Call: Management Details Tariff Mitigation, Store Expansion, and Pricing ActionsJune 10, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeWRBY, GKOS, NARI, and INSP Company DescriptionsGlaukos NYSE:GKOS$106.65 +1.93 (+1.84%) Closing price 03:59 PM EasternExtended Trading$106.56 -0.09 (-0.08%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Inspire Medical Systems NYSE:INSP$139.27 +4.82 (+3.58%) Closing price 03:59 PM EasternExtended Trading$139.30 +0.03 (+0.02%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.Inari Medical NASDAQ:NARI$79.97 0.00 (0.00%) As of 02/19/2025Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.Warby Parker NYSE:WRBY$22.22 -0.05 (-0.20%) Closing price 03:59 PM EasternExtended Trading$22.20 -0.03 (-0.11%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
